Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm

Cancers

Stephanie C. Tucker¹  Kenneth V. Honn¹  Piotr Skalij²  Piotr Tokajuk²  Marek Z. Wojtukiewicz²  Anna M. Wojtukiewicz³  Barbara Politynska³ 

[1] Bioactive Lipids Research Program, Department of Pathology-School of Medicine, Detroit, MI 48202, USA;Department of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, Poland;Department of Philosophy and Human Psychology, Medical University of Białystok, 37 Szpitalna St., 15-295 Białystok, Poland;

关键词: thrombosis;    cancer;    treatment;    prophylaxis;    anticoagulants;    DOAC;   

DOI  :  10.3390/cancers12051144

来源: DOAJ

【 摘 要 】

Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.

【 授权许可】

Unknown